



IBA adds two treatment rooms to South China Guangdong collaboration

IBA, already involved in the first phase of the construction of a proton therapy center in Guangzhou, China, signs an agreement for two additional state-of-the-art gantry treatment rooms

Louvain-la-Neuve, Belgium, July 1st, 2015 - IBA (Ion Beam Applications SA), the world's leading provider of proton therapy solutions for the treatment of cancer, today announces that it has signed an extension to the collaboration agreement with Guangdong Hengju Medical Technologies Co. Limited. This binding agreement for two additional gantry treatment rooms, equipped with the next generation Pencil Beam Scanning capability, is worth approximately EUR 20 million to IBA.

In December 2014, IBA signed its first collaboration agreement with Guangdong Hengju Medical Technologies Co. Limited to jointly install the first proton therapy system in South China. This agreement is worth approximately EUR 30 million to IBA. With a total of three rooms planned, the facility is expected to open in 2017.

Olivier Legrain, Chief Executive Officer, IBA, commented: "This extension of our collaboration with Guangdong Hengju Medical Technologies Co. Limited confirms IBA's position as a trusted partner for the development and delivery of proton therapy treatment facilities around the world. We are delighted to have built upon our original contribution to this collaboration to jointly install the first proton therapy system in South China."

Mr Xiao Xue, Chairman, Guangdong Hengjian Investment Holding Co Ltd, commented: "Guangdong Hengju Medical Technologies Co. Limited Proton Therapy facility enjoys full support from various Chinese governments, and is listed as a National Key Project. This second collaboration with IBA, the global leader in proton therapy, is very significant and is an important milestone for future long term partnership between both companies."

Mr Wang Jian, Executive Director Guangdong Hengju Medical Technologies Co Ltd, added: "The signing of this second agreement will increase the rate of future developments and provide the chance to train our team and increase the level of medical expertise in Guangdong Province."

***** END *****

Notes to Editors

About Proton Therapy

Proton Therapy is considered the most advanced and targeted cancer radiotherapy treatment due to its superior dose distribution and fewer side effects. Protons deposit the majority of their effective energy within a precisely controlled range, directly within the tumor, sparing healthy surrounding tissue. Higher doses can be delivered to the tumor without increasing the risk of side effects and long-term complications, thereby improving patient outcomes and quality of life. Today, more than half of all



proton therapy clinical facilities worldwide are equipped with IBA systems. This includes 18 proton therapy centers currently in operation and 19 additional centers under development.

While proton therapy today represents less than 1% of radiotherapy treatments, studies estimate that more than 17% of patients treated by radiotherapy would benefit from being treated by this technique.

About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The Company is the worldwide technology leader in the field of proton therapy, the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full scale proton therapy centers as well as compact, single room systems. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry.

Headquartered in Belgium and employing about 1100 people worldwide, IBA has installed systems across the world, from Europe and the US and to the emerging markets. IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: www.iba-worldwide.com

About Guangdong Heng Ju Medical Technologies Co Limited

Guangdong Hengjian Investment Holding Co. Ltd is the financing and investment platform of the Guangdong provincial government. Guangdong Hengju Medical Technologies Co Limited is the first company in China focusing on the development and expansion of proton therapy in China under the spirit of 'Government Supported, Corporatized Management and Market Oriented'.

For further information please contact:

IBA

Jean-Marc Bothy
Chief Financial Officer
+32 10 475 890
Investorrelations@iba-group.com

Thomas Ralet
Vice-President Corporate Communication
+32 10 475 890
Communication@iba-group.com

For media and investor enquiries:

Consilium Strategic Communications

Amber Fennell, Matthew Neal, Ivar Milligan,
Jessica Hodgson
+44 (0) 20 3709 5700
IBA@consilium-comms.com

Rx Communications Group (US)

Melody Carey
+ 1 917 322 2571
mcarey@RxIR.com